Cost-effectiveness of pre-exposure prophylaxis for HIV: A review

Current Opinion in HIV and AIDS

Volumn 7, Issue 6, 2012, Pages 587-592

  Schackman, Bruce R ^a   Eggman, Ashley A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cost effectiveness; HIV prevention; modeling; pre exposure prophylaxis

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR DISOPROXIL;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HIGH RISK POPULATION; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MALE HOMOSEXUAL; MONTE CARLO METHOD; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SOUTH AFRICA; STATISTICAL MODEL; UNITED STATES; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; SOUTH AFRICA; UNITED STATES;

EID: 84868360548     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283582c8b     Document Type: Review

References (30)

1. US Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012. http://www.fda.gov/News Events/Newsroom/PressAnnouncements/ucm312210.htm. [Accessed 16 July 2012]
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
3. University of Washington International Clinical Research Center Partners PrEP Study. Pivotal study finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa. 2012. http://depts.washington.edu/uwicrc/research/studies/files/PrEP-PressRelease- UW-13Jul2011.pdf. [Accessed 19 June 2012]
4. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
5. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-422.
6. US National Institutes of Health. Safety and effectiveness of tenofovir 1% Gel, tenofovir disoproxil fumarate, and emtricitabine/tenofovir disoproxil fumarate tablets in preventing HIV in women NCT00705679. 2012. http://clinicaltrials. gov/ct2/show/NCT00705679?term=VOICE+HIV&rank=7. [Accessed 20 June 2012]
7. US National Institutes of Health. Safety and effectiveness of tenofovir gel in the prevention of human immunodeficiency virus (HIV-1) infection in women and the effects of tenofovir gel on the incidence of herpes simplex virus (HSV-2) infection NCT01386294. 2012. http://clinicaltrials.gov/ct2/show/ NCT01386294?term=FACTS+001&rank=1. [Accessed 20 June 2012]
8. Paxton LA, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: what if it works? Lancet 2007; 370:89-93.
9. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50 000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008; 8:165-178.
10. Braithwaite RS, Fiellin DA, Nucifora K, et al. Evaluating interventions to improve antiretroviral adherence: how much of an effect is required for favorable value? Value Health 2010; 13:535-542.
11. Farnham PG, Sansom SL, Hutchinson AB. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Med Decis Making 2012; 32:459-469.
12. Gopalappa C, Farnham PG, Hutchinson AB, Sansom SL. Cost-effectiveness of the national HIV/AIDS Strategy (NHAS) goal of increasing linkage to care for HIV-infected persons. J Acquir Immune Defic Syndr 2012; 61:99-105.
13. World Health Organization. CHOosing interventions that are cost-effective (WHO-CHOICE): cost-effectiveness thresholds. 2009. http://www.who.int/choice/ costs/CER-thresholds/en/index.html. [Accessed: 26 June 2012]
14. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices - budget impact analysis. Value Health 2007; 10:336-347.
15. Cost-Effectiveness of Preventing AIDS Complications (CEPAC). 2012. http://web2.research.partners.org/cepac/mainpage.html. [Accessed 19 June 2012]
16. Ciaranello AL, Perez F, Maruva M, et al. WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. PLoS One 2011; 6:e20224.
17. Pretorius C, Stover J, Bollinger L, et al. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One 2010; 5:e13646.
18. Baggaley RF, Fraser C. Modelling sexual transmission of HIV: testing the assumptions, validating the predictions. Curr Opin HIV AIDS 2010; 5:269- 276.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost effectiveness in health and medicine. Oxford, UK: Oxford University Press; 1996.
20. Drummond MF, Schulpher MJ, Torrance GW, et al. Methods for the economic evaluation of healthcare programmes. 3rd ed. Oxford, UK: Oxford University Press; 2005.
21. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008; 22:1829-1839.
22. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and costeffectiveness. Clin Infect Dis 2009; 48:806-815.
23. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of pre-exposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 2012; 156:541-550.
24. Seage GR 3rd, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol 2001; 153:619-627.
25. Kaiser Family Foundation. The Ryan White Program. 2011. http://www. kff.org/hivaids/upload/7582-06.pdf. [Accessed 26 June 2012]
26. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8:e1001123.
27. Lingappa JR, Kahle E, Mugo N, et al. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One 2009; 4:e5272.
28. Lingappa JR, Baeten JM, Wald A, et al. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010; 375:824-833.
29. Walensky RP, Park JE, Wood R, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis 2012; 54:1504-1513.
30. Country Progress Report on the Declaration of Commitment on HIV/AIDS. (Accessed 14 September 2012, at http://data.unaids.org/pub/Report/2008/south- africa-2008-country-progress-report-en.pdf.)